Jennifer K. Thompson

Dual plasmepsin IX and X inhibitors are refractory to development of resistance

Abstract Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment, but emerging resistance threatens their efficacy. The potential for the development of drug resistance against plasmepsin X (PMX)-selective inhibitors and dual plasmepsin IX/X (PM...